Synopsys is Fundamentally Immune to AI Disruption Fears, BofA Says

MT Newswires Live
02/26

Synopsys (SNPS) is fundamentally immune to artificial intelligence disruption fears as its complex tools remain crucial to expensive design processes, BofA Securities said in a Wednesday research report.

The company's joint development of services with Ansys, expected to start rolling out in H1, could drive upside to fiscal 2027 and 2028 estimates, analysts wrote.

The company saw momentum in hardware in fiscal Q1, including a "marquee emulation" win versus Cadence Design Systems' (CDNS) ASIC-driven platform at an AI high-performance computing client, indicating that the gap between the hardware performance of the companies could be smaller than realized, according to the note.

The brokerage said it reiterated its buy rating on the stock and cut its price target to $515 per share from $560.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10